Vol 8, Supp. A (2017)
Case report
Published online: 2017-12-21

open access

Page views 568
Article views/downloads 547
Get Citation

Connect on Social Media

Connect on Social Media

Leczenie pomalidomidem chorego na szpiczaka plazmocytowego po przeszczepieniu allogenicznych krwiotwórczych komórek macierzystych od dawcy niespokrewnionego

Kazimierz Hałaburda1

Abstract

The case report presents IgA plasma cell myeloma patient treated with chemotherapy, botrezomib,
autologous hematopoietic stem cell transplantation, lenalidomide, unrelated donor allogeneic hematopoietic stem cell transplantation and finally pomalidomide (POM). In spite of lack of deep,
long-term response after any of the therapies, the combined treatment using all modalities currently
available in Poland led to prolonged survival of the patient. Of note, POM employed as sixth-line
therapy showed good efficacy and relatively few side effects over a 27-cycle treatment period.

Article available in PDF format

View PDF (Polish) Download PDF file



Hematology in Clinical Practice